Inhibitory effect of acetyl-11-keto-β-boswellic acid on androgen receptor by interference of Sp1 binding activity in prostate cancer cells

Biochemical Pharmacology

Volumn 75, Issue 11, 2008, Pages 2112-2121

  Yuan, Hui Qing ^a   Kong, Feng ^a   Wang, Xiao Ling ^a   Young, Charles Y F ^b   Hu, Xiao Yan ^a   Lou, Hong Xiang ^a  

^a SHANDONG UNIVERSITY   (China)

^b MAYO CLINIC   (United States)

Author keywords

Acetyl 11 keto boswellic acid; Androgen receptor; Cell cycle arrest; Prostate cancer cell lines; Sp1

Indexed keywords

ACETYL 11 OXO BETA BOSWELLIC ACID; ANDROGEN RECEPTOR; BOSWELLIC ACID; CYCLIN D1; LUCIFERASE; PROSTATE SPECIFIC ANTIGEN; TRANSCRIPTION FACTOR SP1;

ARTICLE; BINDING AFFINITY; CANCER CELL; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; DRUG EFFECT; HUMAN; HUMAN CELL; MITOSIS INHIBITION; PRIORITY JOURNAL; PROSTATE CANCER;

CELL LINE, TUMOR; DNA; G1 PHASE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; PROSTATIC NEOPLASMS; PROTEIN BINDING; RECEPTORS, ANDROGEN; SP1 TRANSCRIPTION FACTOR; TRITERPENES;

EID: 43049103404     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2008.03.005     Document Type: Article

References (33)

1. Culig Z. Role of the androgen receptor axis in prostate cancer. Urology 62 (2003) 21-26
2. Feldman B.J., and Felman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 1 (2001) 34-45
3. Jenster G. Ligand-independent activation of androgen receptor in prostate cancer by growth factors and cytokines. J Pathol 191 (2000) 227-228
4. Chan J.M., Gann P.H., and Giovannucci E.L. Role of diet in prostate cancer development and progression. J Clin Oncol 23 (2005) 8152-8160
5. Klein E.A. Chemoprevention of prostate cancer. Annu Rev Med 57 (2006) 49-63
6. Singh G.B., and Atal C.K. Pharmcology of an extract of salai guggal ex-Boswellia serrata, a new non-steroidal anti-inflammatory agent. Agents Actions 18 (1986) 407-412
7. Kimmatkar N., Thawani V., Hingorani L., and Khiyani R. Efficacy and tolerability of Boswellia serrata extract in treatment of osteoarthritis of knee: a randomized double blind placebo controlled trial. Phytomedicine 10 (2003) 3-7
8. Tang X., Hu Y., and Hu G.Q. Anticancer action of Xihuang pill combined with 5-Fu. Herald Med 24 (2005) 757-759
9. Li L.F., Chen R.S., and Liu X.M. Xihuangwan induce Bel-7402 cell apoptosis and the change of intracellular-free calcium level in the process. Chin J Clin Hepatol 19 (2003) 362-363
10. Xiong Y., Kong X.Y., Chen R.S., Jin Q.W., and Liu X.M. The morphological study on the induction of apoptosis in vitro by chinese herbal medicine Xihuangwan. Chin J Clin Gastroenterol 13 (2001) 82-84
11. el-Khadem H., el-Shafei Z.M., el-Sekeily M.A., and Rahman M.M. Derivatives of boswellic acids. Planta Med 22 (1972) 157-159
12. Proietti G., Strapaghetti G., and Corsano S. Triterpenes of Boswellia frereana. Planta Med 41 (1981) 417
13. Ammon H.P. Boswellic acids in chronic inflammatory diseases. Planta Med 72 (2006) 1100-1116
14. Jing Y., Nakajo S., Xia L., Nakaya K., Fang Q., Waxman S., et al. Boswellic acids acetate induces differentiation and apoptosis in leukemia cell lines. Leuk Res 23 (1999) 43-50
15. Liu J.J., Huang B., and Hooi S.C. Acetyl-keto-β-boswellic acid inhibits cellular proliferation through a p21-dependent pathway in colon cancer cells. Br J Pharmacol 148 (2006) 1099-1107
16. Syrovets T., Gschwend J.E., Büchele B., Laumonnier Y., Zugmaier W., Genze F., et al. Inhibition of IκB kinase activity by acetyl-boswellic acids promotes apoptosis in androgen-independent PC-3 prostate cancer cells in vitro and in vivo. J Biol Chem 280 (2005) 6170-6180
17. Liu J.J., Nilsson A., Oredsson S., Badmaev V., and Duan R.D. Keto- and acetyl-keto-boswellic acids inhibit proliferation and induce apoptosis in Hep G2 cells via a caspase-8 dependent pathway. Int J Mol Med 10 (2002) 501-505
18. Glaser T., Winter S., Groscurth P., Safayhi H., Sailer E.R., Ammon H.P., et al. Boswellic acids and malignant glioma: induction of apoptosis but no modulation of drug sensitivity. Br J Cancer 80 (1999) 756-765
19. Takada Y., Ichikawa H., Badmaev V., and Aggarwal B. Acetyl-11-keto-β-boswellic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing NF-κB and NF-κB-regulated gene expression. J Immunol 176 (2006) 3127-3140
20. Zhao W., Entschladen F., Liu H., Niggermann B., Fang Q., Zaenker K.S., et al. Boswellic acid acetate induces differentiation and apoptosis in highly metastatic melanoma and fibrosarcoma cells. Cancer Detect Prev 27 (2003) 67-75
21. Park Y.S., Lee J.H., Harwalkar J.A., Bondar J., Safayhi H., and Golubic M. Acetyl-11-keto-beta-boswellic acid (AKBA) is cytotoxic for meningioma cells and inhibits phosphorylation of the extracellular-signal regulated kinase 1 and 2. Adv Exp Med Biol 507 (2002) 387-393
22. T method. Methods 25 (2001) 402-408
23. Yuan H.Q., Gong A.Y., and Young C.Y.F. Involvement of transcription factor Sp1 in quercetin-mediated inhibitory effect on the androgen receptor in human prostate cancer cells. Carcinogenesis 26 (2005) 793-801
24. Ren F.G., Zhang S.B., Mitchell S.H., Butler R., and Young C.Y.F. Tea polyphenols down-regulate the expression of the androgen receptor in LNCaP prostate cancer cells. Oncogene 19 (2000) 1924-1932
25. Jiang S.W., and Eberhardt N.L. A micro-scale method to isolate DNA-binding proteins suitable for quantitative comparison of expression in levels from transfection cells. Nucleic Acids Res 23 (1995) 3607-3608
26. Zegarra-Moro O.L., Schmidt L.J., Huang H., and Tindall D.J. Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res 62 (2002) 1008-1013
27. Eder I.E., Hoffmann J., Rogatsch H., Schäfer G., Zopf D., Bartsch G., et al. Inhibition of LNCaP prostate tumor growth in vivo by an antisense oligonucleotide directed against the human androgen receptor. Cancer Gene Ther 9 (2002) 117-125
28. Faber P.W., van Rooij H.C., Schipper H.J., Brinkmann A.O., and Trapman J. Two different, overlapping pathways of transcription initiation are active on the TATA-less human androgen receptor promoter. The role of Sp1. J Biol Chem 268 (1993) 9296-9301
29. Cabral D.F., Santos A., Ribeiro M.L., Mesquita J.C., Carvalho-Salles A.B., and Hackel C. Rarity of DNA sequence alterations in the promoter region of the human androgen receptor gene. Braz J Med Bio Res 37 (2004) 1789-1794
30. Petrylak D.P. The current role of chemotherapy in metastatic hormone-refractory prostate cancer. Urology 65 (2005) 3-7 [discussion 7-8]
31. Morris J.D.H., Pramanik R., Zhang X., Carey A.M., Ragavan N., Martin F.L., et al. Selenium- or quercetin-induced retardation of DNA synthesis in primary prostate cells occurs in the presence of a concomitant reduction in androgen-receptor activity. Cancer Lett 239 (2006) 111-122
32. Suh J., Payvandi F., Edelstein L.C., Amenta P.S., Zong W.X., Gelinas C., et al. Mechanisms of constitutive NFKB activation in human prostate cancer cells. Prostate 52 (2002) 183-200
33. Zerbini L.F., Wang Y., Cho J.Y., and Libermann T.A. Constitutive activation of nuclear factor kappa B p50/p65 and Fra-1 and Jun D is essential for deregulation interleukin 6 expression in prostate cancer. Cancer Res 63 (2003) 2206-2215